Should New HEPZATO Subgroup Data and Delcath's Targeted Strategy Require Action From DCTH Investors? [Yahoo! Finance]
Delcath Systems, Inc. (DCTH)
US:NASDAQ Investor Relations:
delcath.com/investors
Company Research
Source: Yahoo! Finance
melanoma were published in the Journal of Cancer Research and Clinical Oncology, detailing efficacy and safety outcomes across different patient characteristics. The publication highlights that patients with lower liver tumor burden and low or normal LDH levels experienced meaningfully longer progression-free and overall survival, with many responses emerging after multiple treatment cycles and no evidence of cumulative toxicity. We'll now examine how these subgroup findings, particularly the stronger outcomes in patients with lower tumor burden, may influence Delcath's investment narrative. We've found 14 US stocks that are forecast to pay a dividend yield of over 6% next year . See the full list for free. To own Delcath, you essentially have to believe that HEPZATO/CHEMOSAT can gain meaningful commercial traction as a differentiated option in liver-directed cancer care. The new FOCUS subgroup data reinforces clinical credibility, but it does not materially change the near te
Show less
Read more
Impact Snapshot
Event Time:
DCTH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DCTH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DCTH alerts
High impacting Delcath Systems, Inc. news events
Weekly update
A roundup of the hottest topics
DCTH
News
- Delcath Systems (NASDAQ:DCTH) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.MarketBeat
- Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial ResultsBusiness Wire
- Delcath Systems publishes results from subgroup analyses of FOCUS study [Yahoo! Finance]Yahoo! Finance
- Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma [Yahoo! Finance]Yahoo! Finance
- Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal MelanomaBusiness Wire
DCTH
Earnings
- 11/4/25 - In-Line
DCTH
Sec Filings
- 11/25/25 - Form 4
- 11/20/25 - Form 8-K
- 11/13/25 - Form 4
- DCTH's page on the SEC website